Ubamatamab shows durable responses in low-grade serous ovarian cancer study
The study is early-stage and involves a small number of patients, but it is being used to plan a larger confirmatory trial.
What the study found
The late-breaking data from an ongoing trial of ubamatamab in LGSOC reported a 73% objective response rate in a group receiving the highest dose. Objective response means visible reduction of tumor size on scans. LGSOC is a rarer form of ovarian cancer that often resists standard chemotherapy, so these early results are notable for a targeted antibody approach.
Who is affected by this news
The findings concern adults with recurrent and heavily pre-treated low-grade serous ovarian cancer. LGSOC is distinct from the more common high-grade ovarian cancers and can be less responsive to traditional chemotherapy. The trial involves a small group of patients and is not yet practice-changing. Regeneron is enrolling additional patients at the same dose to prepare for a larger Phase 3 trial.
What comes next and practical implications
Next steps include expanding the study to a larger group of patients in a Phase 3 trial to confirm the early signals of efficacy and monitor safety in a broader population. If a Phase 3 trial confirms benefit, ubamatamab could become a new treatment option for LGSOC. Patients should not seek or expect this therapy outside of a clinical trial until regulatory reviews are completed. Clinicians may discuss trials as an option for eligible patients with recurrent LGSOC.
Limitations and questions to watch
The data come from a small, early-stage study and may not reflect results in the broader patient population. Details such as long-term safety, overall survival, and how ubamatamab compares with existing therapies remain to be seen in larger trials. Regulatory approval depends on confirmatory evidence from Phase 3 studies and a favorable risk-benefit assessment.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- investingnews.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.